Use of aldosterone antagonists in heart failure.

CONTEXT Aldosterone antagonists are recommended for patients with moderate to severe heart failure (HF) and systolic dysfunction. Prior studies suggest underuse of aldosterone antagonists in eligible patients as well as overuse in settings in which therapy may be harmful. OBJECTIVE To examine aldosterone antagonist prescription based on HF management guideline criteria, investigator-defined appropriateness criteria, and trends over time in patients hospitalized with heart failure. DESIGN, SETTING, AND PATIENTS Observational analysis of 43,625 patients admitted with HF and discharged home from 241 hospitals participating in the Get With The Guidelines-HF quality improvement registry between January 2005 and December 2007. MAIN OUTCOME MEASURES Prescription and predictors of use of aldosterone antagonists, based on guideline criteria. RESULTS Among 12,565 patients eligible for aldosterone antagonist therapy, 4087 (32.5%) received an aldosterone antagonist at discharge, and treatment increased modestly from 28% to 34% over the study period. There was also wide variation in aldosterone antagonist use among hospitals (0%-90.6%). Aldosterone antagonist use in eligible patients was associated with younger age (adjusted odds ratio [OR], 0.85; 95% confidence interval [CI], 0.82-0.88), African American race/ethnicity (adjusted OR, 1.17; 95% CI, 1.04-1.32), lower systolic blood pressure (adjusted OR, 0.94; 95% CI, 0.92-0.95), history of implantable cardioverter-defibrillator use (adjusted OR, 1.51; 95% CI, 1.34-1.69), depression (adjusted OR, 1.15; 95% CI, 1.01-1.30), alcohol use (adjusted OR, 1.23; 95% CI, 1.02-1.50), and pacemaker implantation (adjusted OR, 1.21; 95% CI, 1.06-1.38), and with having no history of renal insufficiency (adjusted OR, 0.85; 95% CI, 0.75-0.96). Applying serum creatinine and potassium appropriateness criteria, inappropriate and potentially inappropriate use of aldosterone antagonist therapy was low and did not change over the 3-year study period. CONCLUSIONS Less than one-third of eligible patients hospitalized for HF and participating in a quality improvement registry received HF guideline-recommended aldosterone antagonist therapy. Use of aldosterone antagonist therapy among patients with documented contraindications was low.

[1]  C. Yancy,et al.  Influence of hospital length of stay for heart failure on quality of care. , 2008, The American journal of cardiology.

[2]  F. McAlister,et al.  Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. , 2008, European heart journal.

[3]  M. Komajda,et al.  Cardiologists' awareness and perceptions of guidelines for chronic heart failure. The ADDress your Heart survey , 2008, European journal of heart failure.

[4]  C. Yancy,et al.  Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. , 2007, JAMA.

[5]  R. Platt,et al.  Laboratory Evaluation of Potassium and Creatinine Among Ambulatory Patients Prescribed Spironolactone: Are We Monitoring for Hyperkalemia? , 2007, The Annals of pharmacotherapy.

[6]  P. Ponikowski,et al.  EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. , 2006, European heart journal.

[7]  R. Katholi,et al.  Use and side‐effect profile of spironolactone in a private cardiologist's practice , 2006, Clinical cardiology.

[8]  F. Isobe,et al.  Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil , 2005, Journal of clinical pharmacy and therapeutics.

[9]  S. Gottlieb,et al.  The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. , 2005, Journal of the American College of Cardiology.

[10]  C. Gross,et al.  Adoption of Spironolactone Therapy for Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction in the United States, 1998–2001 , 2005, Circulation.

[11]  K. Tamirisa,et al.  Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. , 2004, American heart journal.

[12]  Lynn A Smaha,et al.  The American Heart Association Get With The Guidelines program. , 2004, American heart journal.

[13]  B. Palmer.  Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. , 2004, The New England journal of medicine.

[14]  A. Laupacis,et al.  Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study , 2004 .

[15]  D. Atar,et al.  How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? , 2004, Journal of cardiac failure.

[16]  R. Gliklich,et al.  Using "get with the guidelines" to improve cardiovascular secondary prevention. , 2003, Joint Commission journal on quality and safety.

[17]  B. Bozkurt,et al.  Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. , 2003, Journal of the American College of Cardiology.

[18]  A. Cheung,et al.  Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency. , 2002, Anesthesia and analgesia.

[19]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[20]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[21]  P. Albert,et al.  Models for longitudinal data: a generalized estimating equation approach. , 1988, Biometrics.